Axel Capital Management Exits Position in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Axel Capital Management has sold out all of its stake in Eli Lilly and Co during the most recent quarter, according to the disclosure filed by the company on Aug 11, 2016 with the SEC. The investment management company has sold out 20,260 shares of Eli Lilly and Co which is valued at $1,625,257.

Other Hedge Funds, Including , Bluemountain Capital Management reduced its stake in LLY by selling 3,399 shares or 50.81% in the most recent quarter. The Hedge Fund company now holds 3,291 shares of LLY which is valued at $264,004. Eli Lilly and Co makes up approx 0.01% of Bluemountain Capital Management’s portfolio. Brc Investment Management added LLY to its portfolio by purchasing 39,835 company shares during the most recent quarter which is valued at $3,248,943. Eli Lilly and Co makes up approx 0.55% of Brc Investment Management’s portfolio.Sigma Planning Corp boosted its stake in LLY in the latest quarter, The investment management firm added 149 additional shares and now holds a total of 13,229 shares of Eli Lilly and Co which is valued at $1,079,354. Eli Lilly and Co makes up approx 0.14% of Sigma Planning Corp’s portfolio.Farmers Merchants Investments Inc reduced its stake in LLY by selling 125 shares or 0.41% in the most recent quarter. The Hedge Fund company now holds 30,052 shares of LLY which is valued at $2,412,575. Eli Lilly and Co makes up approx 0.26% of Farmers Merchants Investments Inc’s portfolio.

Eli Lilly and Co opened for trading at $79.68 and hit $79.97 on the upside on Tuesday, eventually ending the session at $79.57, with a gain of 0.35% or 0.28 points. The heightened volatility saw the trading volume jump to 34,07,537 shares. Company has a market cap of $87,833 M.

On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Leave a Reply

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.